Oncotherapy Solutions
Oncotherapy Solutions LLC aims to be a global leader in developing novel peptide drug conjugates and bispecific drug conjugates for treating drug-resistant and metastatic solid tumors. The company is committed to innovation in biotechnology, developing targeted, effective, and safer solutions for cancer treatment, addressing tumor heterogeneity and drug resistance.
Industries
Nr. of Employees
small (1-50)
Oncotherapy Solutions
Not specified in the provided content.
Products
Lead peptide drug conjugate (preclinical candidate)
A lead peptide–drug conjugate targeting a tumor‑associated receptor with reported high stability in human plasma in vitro and demonstrated complete tumor growth inhibition in a TNBC mouse model after a single intravenous dose; toxicology studies reported no adverse effects on body weight, white blood cells or normal organs. Planned activities include IND‑enabling studies and Phase 1/2a clinical trial initiation.
Second peptide drug conjugate (preclinical candidate)
A second peptide–drug conjugate targeting a different tumor‑associated receptor intended for use as monotherapy or in combination with the lead candidate; planned preclinical evaluation.
Bispecific drug conjugates (design stage)
Design and planned testing of bispecific drug conjugates intended to address tumor heterogeneity and treat advanced/metastatic solid tumors.
Lead peptide drug conjugate (preclinical candidate)
A lead peptide–drug conjugate targeting a tumor‑associated receptor with reported high stability in human plasma in vitro and demonstrated complete tumor growth inhibition in a TNBC mouse model after a single intravenous dose; toxicology studies reported no adverse effects on body weight, white blood cells or normal organs. Planned activities include IND‑enabling studies and Phase 1/2a clinical trial initiation.
Second peptide drug conjugate (preclinical candidate)
A second peptide–drug conjugate targeting a different tumor‑associated receptor intended for use as monotherapy or in combination with the lead candidate; planned preclinical evaluation.
Bispecific drug conjugates (design stage)
Design and planned testing of bispecific drug conjugates intended to address tumor heterogeneity and treat advanced/metastatic solid tumors.
Services
Collaborative licensing and partnership arrangements to advance preclinical drug conjugate programs toward IND‑enabling studies and clinical trials.
Collaborative licensing and partnership arrangements to advance preclinical drug conjugate programs toward IND‑enabling studies and clinical trials.
Expertise Areas
- Peptide drug conjugate development
- Bispecific drug conjugate design
- Preclinical oncology efficacy testing
- Preclinical toxicology and PK/PD studies
Key Technologies
- Peptide–drug conjugates (PDCs)
- Bispecific drug conjugates
- In‑vivo tumor models (orthotopic, SCID, PDX, humanized mice)
- Pharmacokinetics and biodistribution studies
News & Updates
Oncotherapy Solutions LLC showcased its most advanced preclinical program at the event held at the Seattle Convention Center on April 17-18, 2024.
The company filed a PCT patent application to expand protection outside the US and is progressing towards IND-enabling studies for its drug conjugates targeting various cancers, with plans to initiate clinical trials.
Oncotherapy Solutions LLC filed a US Non-Provisional patent application covering its drug conjugates.
The company filed a US Provisional patent application covering the method of making and using its drug conjugates.
The company completed Phase I SBIR grant studies demonstrating the efficacy and safety of its lead drug conjugate in preclinical models.
Oncotherapy Solutions was awarded a Phase I SBIR grant to perform further oncology and immuno-oncology preclinical studies.
Oncotherapy Solutions LLC showcased its most advanced preclinical program at the event held at the Seattle Convention Center on April 17-18, 2024.
The company filed a PCT patent application to expand protection outside the US and is progressing towards IND-enabling studies for its drug conjugates targeting various cancers, with plans to initiate clinical trials.
Oncotherapy Solutions LLC filed a US Non-Provisional patent application covering its drug conjugates.
The company filed a US Provisional patent application covering the method of making and using its drug conjugates.
The company completed Phase I SBIR grant studies demonstrating the efficacy and safety of its lead drug conjugate in preclinical models.
Oncotherapy Solutions was awarded a Phase I SBIR grant to perform further oncology and immuno-oncology preclinical studies.